Please Wait.....
Report
Human Insulin Drugs Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)
Market Report I 2023-01-23 I 176 Pages I Mordor Intelligence
Human Insulin Drugs Market is likely to reach USD 32 billion by 2027 at a CAGR greater than 3% over the forecast period.
The COVID-19 pandemic has had a substantial impact on the Human Insulin Drugs Market. Type-1 diabetes patients are impacted more during Covid-19. People with diabetes are having a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes will have more chances to get into serious complications rather than normal people.
Diabetes is associated with many health complications. People with diabetes have a 300% increased risk of being hospitalized compared to those without diabetes, and thus, they incur more healthcare expenses compared to non-diabetic people. Patients with Type 2 diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates. Furthermore, patients attempting to control their blood glucose levels, so as to prevent the long-term complications associated with fluctuations in blood glucose levels, are at greater risk for overcorrection and the resultant hypoglycemia.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Human Insulin Drugs Market Trends
Growing Diabetes Prevalence Driving the Market
All Type 1 diabetes patients and a limited number of Type 2 diabetes patients require daily insulin injections as part of their treatment. As per the ADA, around 67.3% of the cost of diabetes care in the United States is provided by government insurance (including Medicare, Medicaid, and the military). The rest is paid for by private insurance (30.7%) or by the uninsured (2%).
In Canada, the total diabetic population in the country increased by approximately 32% between 2016-2020, and about 8% of the diabetic population has Type 1 diabetes. Many developing countries in North America, including the Caribbean countries, are undergoing an epidemiologic transition and experiencing rapid increases in the prevalence of diabetes.
As of 2021, the prevalence rates for diabetes ranged from 12% to 19% of the population in several countries in the region.
Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the Market.
North America Dominates the Market
North America dominates the global human insulin market, especially the United States, owing to the high prevalence of diabetes in the region because of a sedentary lifestyle. The cost factor is the major concern in the United States, where almost 50% of the insulin revenues for the manufacturers are from the country itself. The United States accounts for the highest sales of long-acting insulin, Lantus, across the world. Most diabetic drug manufacturing companies consider the country as a critical market for improving overall global sales. Lantus is the most administered basal insulin across the world, accounting for a dominant share in the US market. The traditional North American human insulin drugs market is expected to grow during the forecast period, due to its economic affordability to patients. Humulin holds the highest market share, followed by Novolin. There are no generic competitors for the traditional North American human insulin drugs market in the United States.
The United States accounts for the highest sales of Humalog across the world, with over 56% of the market share. The majority of the diabetes drug manufacturing companies consider the country a critical market for improving overall global sales. In the United States, Humalog is available in different varieties under names like Humalog Mix 75/25, Humalog U-100, Humalog U-200, and Humalog Mix 50/50 for the treatment of diabetes.
Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the Human Insulin Drugs Market.
Human Insulin Drugs Market Competitor Analysis
The global human insulin market is highly consolidated with three major manufacturers holding a global market presence, and the remaining manufacturers confined to the other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (Insulin Glargine). Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for the treatment of type-1 and type-2 diabetes mellitus. The fast-acting oral insulin could improve post-prandial glucose control with reduced side effects and greater adherence, thus holding the promise to transform T1D management. Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, focused on the development of oral drug delivery systems, is working to bring the first oral insulin product to market, thus, providing a more convenient, effective, as well as a safer method for delivering insulin therapy.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Basal or Long-acting Insulins (Value and Volume, 2016 - 2027)
5.1.1.1 Lantus (Insulin glargine)
5.1.1.2 Levemir (Insulin detemir)
5.1.1.3 Toujeo (Insulin glargine)
5.1.1.4 Tresiba (Insulin degludec)
5.1.1.5 Basaglar (Insulin glargine)
5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2016 - 2027)
5.1.2.1 NovoRapid/Novolog (Insulin aspart)
5.1.2.2 Humalog (Insulin lispro)
5.1.2.3 Apidra (Insulin glulisine)
5.1.2.4 FIASP (Insulin aspart)
5.1.2.5 Admelog (Insulin lispro)
5.1.3 Traditional Human Insulins (Value and Volume, 2016 - 2027)
5.1.3.1 Novolin/Actrapid/Insulatard
5.1.3.2 Humulin
5.1.3.3 Insuman
5.1.4 Combination Insulins (Value and Volume, 2016 - 2027)
5.1.4.1 NovoMix (Biphasic Insulin aspart)
5.1.4.2 Ryzodeg (Insulin degludec/Insulin aspart)
5.1.4.3 Xultophy (Insulin degludec/Liraglutide)
5.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)
5.1.5 Biosimilar Insulins (Value and Volume, 2016 - 2027)
5.1.5.1 Insulin Glargine Biosimilars
5.1.5.2 Human Insulin Biosimilars
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume, 2016 - 2027)
5.2.1.1.1 Basal or Long-acting Insulins
5.2.1.1.2 Bolus or Fast-acting Insulins
5.2.1.1.3 Traditional Human Insulins
5.2.1.1.4 Combination Insulins
5.2.1.1.5 Biosimilar Insulins
5.2.1.2 Canada (Value and Volume, 2016 - 2027)
5.2.1.2.1 Basal or Long-acting Insulins
5.2.1.2.2 Bolus or Fast-acting Insulins
5.2.1.2.3 Traditional Human Insulins
5.2.1.2.4 Combination Insulins
5.2.1.2.5 Biosimilar Insulins
5.2.1.3 Rest of North America (Value and Volume, 2016 - 2027)
5.2.1.3.1 Basal or Long-acting Insulins
5.2.1.3.2 Bolus or Fast-acting Insulins
5.2.1.3.3 Traditional Human Insulins
5.2.1.3.4 Combination Insulins
5.2.1.3.5 Biosimilar Insulins
5.2.2 Europe
5.2.2.1 France (Value and Volume, 2016 - 2027)
5.2.2.1.1 Basal or Long-acting Insulins
5.2.2.1.2 Bolus or Fast-acting Insulins
5.2.2.1.3 Traditional Human Insulins
5.2.2.1.4 Combination Insulins
5.2.2.1.5 Biosimilar Insulins
5.2.2.2 Germany (Value and Volume, 2016 - 2027)
5.2.2.2.1 Basal or Long-acting Insulins
5.2.2.2.2 Bolus or Fast-acting Insulins
5.2.2.2.3 Traditional Human Insulins
5.2.2.2.4 Combination Insulins
5.2.2.2.5 Biosimilar Insulins
5.2.2.3 Italy (Value and Volume, 2016 - 2027)
5.2.2.3.1 Basal or Long-acting Insulins
5.2.2.3.2 Bolus or Fast-acting Insulins
5.2.2.3.3 Traditional Human Insulins
5.2.2.3.4 Combination Insulins
5.2.2.3.5 Biosimilar Insulins
5.2.2.4 Spain (Value and Volume, 2016 - 2027)
5.2.2.4.1 Basal or Long-acting Insulins
5.2.2.4.2 Bolus or Fast-acting Insulins
5.2.2.4.3 Traditional Human Insulins
5.2.2.4.4 Combination Insulins
5.2.2.4.5 Biosimilar Insulins
5.2.2.5 United Kingdom (Value and Volume, 2016 - 2027)
5.2.2.5.1 Basal or Long-acting Insulins
5.2.2.5.2 Bolus or Fast-acting Insulins
5.2.2.5.3 Traditional Human Insulins
5.2.2.5.4 Combination Insulins
5.2.2.5.5 Biosimilar Insulins
5.2.2.6 Russia (Value and Volume, 2016 - 2027)
5.2.2.6.1 Basal or Long-acting Insulins
5.2.2.6.2 Bolus or Fast-acting Insulins
5.2.2.6.3 Traditional Human Insulins
5.2.2.6.4 Combination Insulins
5.2.2.6.5 Biosimilar Insulins
5.2.2.7 Rest of Europe (Value and Volume, 2016 - 2027)
5.2.2.7.1 Basal or Long-acting Insulins
5.2.2.7.2 Bolus or Fast-acting Insulins
5.2.2.7.3 Traditional Human Insulins
5.2.2.7.4 Combination Insulins
5.2.2.7.5 Biosimilar Insulins
5.2.3 Latin America
5.2.3.1 Mexico (Value and Volume, 2016 - 2027)
5.2.3.1.1 Basal or Long-acting Insulins
5.2.3.1.2 Bolus or Fast-acting Insulins
5.2.3.1.3 Traditional Human Insulins
5.2.3.1.4 Combination Insulins
5.2.3.1.5 Biosimilar Insulins
5.2.3.2 Brazil (Value and Volume, 2016 - 2027)
5.2.3.2.1 Basal or Long-acting Insulins
5.2.3.2.2 Bolus or Fast-acting Insulins
5.2.3.2.3 Traditional Human Insulins
5.2.3.2.4 Combination Insulins
5.2.3.2.5 Biosimilar Insulins
5.2.3.3 Rest of Latin America (Value and Volume, 2016 - 2027)
5.2.3.3.1 Basal or Long-acting Insulins
5.2.3.3.2 Bolus or Fast-acting Insulins
5.2.3.3.3 Traditional Human Insulins
5.2.3.3.4 Combination Insulins
5.2.3.3.5 Biosimilar Insulins
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value and Volume, 2016 - 2027)
5.2.4.1.1 Basal or Long-acting Insulins
5.2.4.1.2 Bolus or Fast-acting Insulins
5.2.4.1.3 Traditional Human Insulins
5.2.4.1.4 Combination Insulins
5.2.4.1.5 Biosimilar Insulins
5.2.4.2 South Korea (Value and Volume, 2016 - 2027)
5.2.4.2.1 Basal or Long-acting Insulins
5.2.4.2.2 Bolus or Fast-acting Insulins
5.2.4.2.3 Traditional Human Insulins
5.2.4.2.4 Combination Insulins
5.2.4.2.5 Biosimilar Insulins
5.2.4.3 China (Value and Volume, 2016 - 2027)
5.2.4.3.1 Basal or Long-acting Insulins
5.2.4.3.2 Bolus or Fast-acting Insulins
5.2.4.3.3 Traditional Human Insulins
5.2.4.3.4 Combination Insulins
5.2.4.3.5 Biosimilar Insulins
5.2.4.4 India (Value and Volume, 2016 - 2027)
5.2.4.4.1 Basal or Long-acting Insulins
5.2.4.4.2 Bolus or Fast-acting Insulins
5.2.4.4.3 Traditional Human Insulins
5.2.4.4.4 Combination Insulins
5.2.4.4.5 Biosimilar Insulins
5.2.4.5 Australia (Value and Volume, 2016 - 2027)
5.2.4.5.1 Basal or Long-acting Insulins
5.2.4.5.2 Bolus or Fast-acting Insulins
5.2.4.5.3 Traditional Human Insulins
5.2.4.5.4 Combination Insulins
5.2.4.5.5 Biosimilar Insulins
5.2.4.6 Vietnam (Value and Volume, 2016 - 2027)
5.2.4.6.1 Basal or Long-acting Insulins
5.2.4.6.2 Bolus or Fast-acting Insulins
5.2.4.6.3 Traditional Human Insulins
5.2.4.6.4 Combination Insulins
5.2.4.6.5 Biosimilar Insulins
5.2.4.7 Malaysia (Value and Volume, 2016 - 2027)
5.2.4.7.1 Basal or Long-acting Insulins
5.2.4.7.2 Bolus or Fast-acting Insulins
5.2.4.7.3 Traditional Human Insulins
5.2.4.7.4 Combination Insulins
5.2.4.7.5 Biosimilar Insulins
5.2.4.8 Indonesia (Value and Volume, 2016 - 2027)
5.2.4.8.1 Basal or Long-acting Insulins
5.2.4.8.2 Bolus or Fast-acting Insulins
5.2.4.8.3 Traditional Human Insulins
5.2.4.8.4 Combination Insulins
5.2.4.8.5 Biosimilar Insulins
5.2.4.9 Philippines (Value and Volume, 2016 - 2027)
5.2.4.9.1 Basal or Long-acting Insulins
5.2.4.9.2 Bolus or Fast-acting Insulins
5.2.4.9.3 Traditional Human Insulins
5.2.4.9.4 Combination Insulins
5.2.4.9.5 Biosimilar Insulins
5.2.4.10 Thailand (Value and Volume, 2016 - 2027)
5.2.4.10.1 Basal or Long-acting Insulins
5.2.4.10.2 Bolus or Fast-acting Insulins
5.2.4.10.3 Traditional Human Insulins
5.2.4.10.4 Combination Insulins
5.2.4.10.5 Biosimilar Insulins
5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2016 - 2027)
5.2.4.11.1 Basal or Long-acting Insulins
5.2.4.11.2 Bolus or Fast-acting Insulins
5.2.4.11.3 Traditional Human Insulins
5.2.4.11.4 Combination Insulins
5.2.4.11.5 Biosimilar Insulins
5.2.5 Middle-East
5.2.5.1 Saudi Arabia (Value and Volume, 2016 - 2027)
5.2.5.1.1 Basal or Long-acting Insulins
5.2.5.1.2 Bolus or Fast-acting Insulins
5.2.5.1.3 Traditional Human Insulins
5.2.5.1.4 Combination Insulins
5.2.5.1.5 Biosimilar Insulins
5.2.5.2 Iran (Value and Volume, 2016 - 2027)
5.2.5.2.1 Basal or Long-acting Insulins
5.2.5.2.2 Bolus or Fast-acting Insulins
5.2.5.2.3 Traditional Human Insulins
5.2.5.2.4 Combination Insulins
5.2.5.2.5 Biosimilar Insulins
5.2.5.3 Egypt (Value and Volume, 2016 - 2027)
5.2.5.3.1 Basal or Long-acting Insulins
5.2.5.3.2 Bolus or Fast-acting Insulins
5.2.5.3.3 Traditional Human Insulins
5.2.5.3.4 Combination Insulins
5.2.5.3.5 Biosimilar Insulins
5.2.5.4 Oman (Value and Volume, 2016 - 2027)
5.2.5.4.1 Basal or Long-acting Insulins
5.2.5.4.2 Bolus or Fast-acting Insulins
5.2.5.4.3 Traditional Human Insulins
5.2.5.4.4 Combination Insulins
5.2.5.4.5 Biosimilar Insulins
5.2.5.5 South Africa (Value and Volume, 2016 - 2027)
5.2.5.5.1 Basal or Long-acting Insulins
5.2.5.5.2 Bolus or Fast-acting Insulins
5.2.5.5.3 Traditional Human Insulins
5.2.5.5.4 Combination Insulins
5.2.5.5.5 Biosimilar Insulins
5.2.5.6 Rest of Middle-East (Value and Volume, 2016 - 2027)
5.2.5.6.1 Basal or Long-acting Insulins
5.2.5.6.2 Bolus or Fast-acting Insulins
5.2.5.6.3 Traditional Human Insulins
5.2.5.6.4 Combination Insulins
5.2.5.6.5 Biosimilar Insulins
6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2016 - 2027)
6.2 Type 2 Diabetes Population (2016 - 2027)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk A/S
7.1.1.1 Overview
7.1.1.2 Products and Strategies
7.1.1.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.1.4 Ratio Analysis (5 Years)
7.1.1.5 Strength and Stability Analysis (5 Years)
7.1.1.6 Recent Developments
7.1.2 Sanofi S.A.
7.1.2.1 Overview
7.1.2.2 Products and Strategies
7.1.2.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.2.4 Ratio Analysis (5 Years)
7.1.2.5 Strength and Stability Analysis (5 Years)
7.1.2.6 Recent Developments
7.1.3 Eli Lilly and Company
7.1.3.1 Overview
7.1.3.2 Products and Strategies
7.1.3.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.3.4 Ratio Analysis (5 Years)
7.1.3.5 Strength and Stability Analysis (5 Years)
7.1.3.6 Recent Developments
7.1.4 Biocon Limited
7.1.4.1 Overview
7.1.4.2 Products and Strategies
7.1.4.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.4.4 Ratio Analysis (5 Years)
7.1.4.5 Strength and Stability Analysis (5 Years)
7.1.4.6 Recent Developments
7.1.5 Pfizer Inc.
7.1.5.1 Overview
7.1.5.2 Products and Strategies
7.1.5.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.5.4 Ratio Analysis (5 Years)
7.1.5.5 Strength and Stability Analysis (5 Years)
7.1.5.6 Recent Developments
7.1.6 Wockhardt
7.1.6.1 Overview
7.1.6.2 Products and Strategies
7.1.6.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.6.4 Ratio Analysis (5 Years)
7.1.6.5 Strength and Stability Analysis (5 Years)
7.1.6.6 Recent Developments
7.1.7 Julphar
7.1.7.1 Overview
7.1.7.2 Products and Strategies
7.1.7.3 Recent Developments
7.1.8 Exir
7.1.8.1 Overview
7.1.8.2 Products and Strategies
7.1.8.3 Recent Developments
7.1.9 Sedico
7.1.9.1 Overview
7.1.9.2 Products and Strategies
7.1.9.3 Recent Developments
7.2 COMPANY SHARE ANALYSIS
7.2.1 Novo Nordisk AS
7.2.2 Sanofi Aventis
7.2.3 Eli Lilly
7.2.4 Other Companies
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security